Target intelligence / Profile preview

TYRO protein tyrosine kinase-binding protein (TYROBP) (TYROBP)

Target
TYROBP
Molecular classification
Receptor, Other
01

Overview

TYRO protein tyrosine kinase-binding protein (TYROBP), also widely known as DNAX-activation protein 12 (DAP12), is a key transmembrane signaling adaptor protein predominantly expressed in myeloid cells, including microglia, macrophages, dendritic cells, and osteoclasts. It contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, which is critical for recruiting and activating spleen tyrosine kinase (Syk) and ZAP-70 to initiate downstream signaling cascades like PI3K/Akt and MAPK. TYROBP does not possess an extracellular ligand-binding domain of its own; instead, it non-covalently pairs with various activating cell-surface receptors, most notably triggering receptor expressed on myeloid cells 2 (TREM2) and TREM1, to orchestrate immune responses, phagocytosis, and cell survival.

In disease states, TYROBP-mediated signaling is heavily implicated in neurodegenerative disorders such as Alzheimer's disease, where the TREM2-TYROBP axis regulates microglial clearance of amyloid-beta plaques. Mutations in TYROBP lead to Nasu-Hakola disease (PLOSL), a rare genetic disorder characterized by presenile dementia and bone cysts. Therapeutic strategies targeting this pathway include TREM2-activating antibodies (e.g., AL002) and small-molecule molecular glues (e.g., VG-3927) that stabilize the TREM2-TYROBP complex to enhance microglial function. Conversely, inhibitors of DAP12 dimerization or multimerization (such as SRI-44049 and H151-AL) are being explored to mitigate hyper-inflammatory responses in conditions like rheumatoid arthritis and acute inflammation.

Other names
DAP12DNAX-activation protein 12KARAPKiller-activating receptor-associated proteinPLOSLPLOSL1
02

Mechanism of action

Drugs targeting the TYROBP/DAP12 pathway act either as agonists that stabilize the TREM2-TYROBP complex to activate downstream ITAM signaling, or as inhibitors that block DAP12 dimerization and multimerization to suppress inflammatory signaling.

03

Biological functions

Signal transductionImmune responseApoptosisOther
04

Disease associations

Neurodegenerative diseaseInflammationCancerOther
05

Safety considerations

Amyloid-related imaging abnormalities (ARIA)Brain volume lossBone remodeling defectsLeukoencephalopathyExcessive neuroinflammation
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

sTREM2p-SYK/SYK ratioSPP1IL-1RAC1q

Beyond the preview

Go deeper on TYRO protein tyrosine kinase-binding protein (TYROBP) (TYROBP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TYRO protein tyrosine kinase-binding protein (TYROBP) (TYROBP).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call